Introduction

Cancer treatment has evolved significantly, encompassing a range of strategies such as surgery, chemotherapy, radiation therapy, targeted therapies such as antibody-drug conjugates (ADCs), and the rapidly advancing field of immuno-oncology (IO). IO therapies, including immune checkpoint inhibitors, T cell engagers, CAR-T cell therapy, and cancer vaccines, are transforming the landscape by harnessing the immune system to recognize and attack tumors. The development of these therapies heavily relies on preclinical testing using animal models.

Biocytogen has established a range of oncology and immuno-oncology models to evaluate the novel cancer therapeutics and combination therapies, including syngeneic models especially based on gene humanized mice, xenograft models utilizing immunodeficient mice, and orthotopic tumor models. We have also developed luciferase-labeled tumor cell lines to enable in vivo imaging for enhanced tumor monitoring. Our pharmacology team brings extensive expertise in conducting in vivo efficacy studies, ex vivo pharmacodynamic (PD) and pharmacokinetic (PK) analyses, as well as in vitro assays, providing comprehensive support for clients’ drug IND applications.

In Vivo Models

Syngeneic Models

Biocytogen's gene humanized mouse models further accelerate human-specific immunotherapies by enabling efficient preclinical in vivo testing.

Learn More

Xenograft Models

We established 200+ CDX models, 270 PDX models and human immune system reconstitution models in B-NDG mice and variants.

Learn More

Orthotopic Models

With orthotopic models, we can closely monitor and accurately quantify primary tumor growth, metastatic activity, and response to therapy scenarios.

Learn More